ExodusPoint Capital Management LP Has $323,000 Stake in Enfusion, Inc. (NYSE:ENFN)

ExodusPoint Capital Management LP decreased its position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 74.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,388 shares of the company's stock after selling 90,779 shares during the quarter. ExodusPoint Capital Management LP's holdings in Enfusion were worth $323,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ENFN. Trexquant Investment LP acquired a new stake in shares of Enfusion in the 4th quarter valued at $604,000. Geode Capital Management LLC lifted its position in shares of Enfusion by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company's stock worth $10,823,000 after buying an additional 21,183 shares during the last quarter. Wellington Management Group LLP boosted its stake in Enfusion by 6.1% in the fourth quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company's stock valued at $10,671,000 after buying an additional 59,700 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Enfusion in the fourth quarter valued at about $2,358,000. Finally, JPMorgan Chase & Co. raised its stake in Enfusion by 45.8% during the fourth quarter. JPMorgan Chase & Co. now owns 303,332 shares of the company's stock worth $3,124,000 after acquiring an additional 95,310 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Neal Pawar sold 14,560 shares of Enfusion stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $165,692.80. Following the completion of the transaction, the chief operating officer now owns 1,217,067 shares of the company's stock, valued at $13,850,222.46. This trade represents a 1.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bronwen Bastone sold 3,126 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the transaction, the insider now owns 221,875 shares in the company, valued at approximately $2,524,937.50. The trade was a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,223 shares of company stock valued at $754,778. 36.44% of the stock is currently owned by company insiders.

Enfusion Stock Performance

Shares of NYSE:ENFN traded down $0.01 during midday trading on Friday, hitting $10.80. 2,461,878 shares of the stock were exchanged, compared to its average volume of 632,273. The business's 50-day moving average price is $11.08 and its 200 day moving average price is $10.41. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 269.94, a P/E/G ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, sell-side analysts expect that Enfusion, Inc. will post 0.06 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ENFN. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Piper Sandler boosted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research note on Monday, December 23rd.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.